A Pharmacodynamic Study of SLM0807, HKB0701 and CJ30001 in Healthy Subject

HK inno.N Corporation0 个研究点目标入组 30 人开始时间: 2010年1月最近更新: 2011年6月27日

适应症

试验速览

阶段: 1 期
状态: 已完成
发起方: HK inno.N Corporation
入组人数: 30
主要终点: AUC0-2h of plasma glucose

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

This trial is conducted to

assess whether SLM0807 alters pharmacodynamics of HKB0701
estimate the pharmacodynamics of HKB0701 after multiple administration of CJ30001 and multiple co-administration of HKB0701/SLM0807 in healthy subject

研究设计

研究类型: Interventional
分配方式: Randomized
干预模型: Crossover
主要目的: Basic Science
盲法: None

入排标准

年龄范围: 20 Years 至 50 Years（Adult）
性别: All
接受健康志愿者: 是

入选标准

•Healthy volunteers who are in age range of 20-50years and the weight range is not exceed ±20% of ideal weight. Ideal weight = [height -100]*0.9
•Subjects with no history of any significant chronic disease
•Subjects with FPG<100mg/dL and 2hr glucose after 75g OGTT<140mg/dL
•Judged to be in good health on the basis of their vital sign, ECG, physical exam and routine laboratory data
•Available for the entire study period
•Willing to adhere to protocol requirements and sign a informed consent form

排除标准

•Subjects who have taken any drugs to induce or inhibit hepatic enzyme activity within 30days prior to drug administration
•Subjects who have symptom of an acute illness within 4 weeks prior to drug administration
•Subjects with a history of clinically significant allergies including drug allergies
•Subjects whose clinical laboratory test values are outside the accepted normal range(Especially,AST or ALT >1.25 times to normal range or total bilirubin > 1.5times to normal range)
•Subjects with a history of drug, caffeine abuse(caffeine drink >5cups/day)
•Subjects with a history of alcohol abuse(alcohol>30g/day) or who have ever drank alcohol within 7 days prior to drug administration
•Heavy smoker ( >10cigarettes/day)
•Subjects who have had a diet known to interfere with the absorption, distribution, metabolism or excretion of drugs (especially, consumption of grapefruit juice)
•Subjects who have donated plasma within 60days prior to drug administration
•Subjects who have participated in a clinical study within 90days prior to drug administration
•Subjects who have received any drugs that might confound the results of the trial in the opinion of principal investigator within 10days prior to drug administration (cimetidine within 7days prior to drug administration)
•Female subjects who are pregnant, breastfeeding or not using medically acceptable birth control

结局指标

主要结局

AUC0-2h of plasma glucose

时间窗: up to 2hrs

△Cmax of plasma glucose

时间窗: up to 2hrs

次要结局

未报告次要终点

研究者

发起方

HK inno.N Corporation

申办方类型

Industry

相似试验

已完成

1 期

A Drug Interaction Study of SLM0807 and HKB0701 in Healthy SubjectsDiabetes Mellitus

NCT01039896HK inno.N Corporation24

已完成

1 期

Drug-Drug Interaction Study to Assess the Effects of Multiple-Dose Administration of K-877 on the Pharmacodynamics and the Pharmacokinetics of Multiple-Dose Administration of Warfarin in Healthy Adult VolunteersHealthy

NCT02719431Kowa Research Institute, Inc.20

已完成

1 期

Pharmacodynamics and Pharmacokinetics of Empagliflozin and Torasemide in Patients With Type 2 DiabetesDiabetes Mellitus, Type 2

NCT01276288Boehringer Ingelheim23

已完成

2 期

A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell TumorEwing-Like SarcomaEwing Sarcoma

NCT05275426Memorial Sloan Kettering Cancer Center14

已完成

1 期

Pharmacokinetic Drug-Drug Interaction Study Between K-877 and CSG452 in Healthy Adult VolunteersHealthy

NCT04237597Kowa Research Institute, Inc.20